Dr. Mark L. Metersky, MD

Dr. Metersky practices at Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut.

Dr. Metersky's NPI, 1881692044, was assigned on July 12, 2005. Dr. Metersky graduated from New York University School of Medicine in 1985. Dr. Metersky's Connecticut license number on file is 032221.

Dr. Metersky's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD, at 263 Farmington Ave, Farmington, CT 06030.

Dr. Metersky's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut. Dr. Metersky is also affiliated with UConn John Dempsey Hospital. The medical group on file is UConn Medical Group. Dmand AI also links Dr. Metersky to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Metersky practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Metersky's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Metersky is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Metersky's licenses on file in 3 states: Connecticut, California and Florida.

Dmand AI lists asthma, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pneumonia, pulmonary fibrosis and sleep apnea among the conditions Dr. Metersky treats.

CMS data shows 311 Medicare services from Dr. Metersky across 7 procedure codes in 2024, for 103 Medicare patients. Medicare paid $13,660 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 103 Medicare patients who saw Dr. Metersky in 2024. The largest group is 75 to 84, with 47 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Metersky's median patient age at 74, with 54% women.

In 2024, Dr. Metersky wrote 671 Medicare Part D claims for 114 patients. 55% of them were for generic drugs. CMS names the drug for 564 of them, across 24 drugs with 11 or more claims each, at $257,768 in total drug cost. In 2023, CMS named 822 claims across 26 drugs.

Dr. Metersky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Metersky as offering telehealth.

Dmand AI links 223 papers to Dr. Metersky, published from 2003 to 2025. 2024 was the busiest year, with 13. The most frequent topics are Pneumonia, Bronchiectasis and Anti-Bacterial Agents. Dr. Metersky has published most often in Chest. Dr. Metersky's most frequent co-authors are Timothy R. Aksamit, MD, Charles L. Daley, MD and Anne Elizabeth O'Donnell.

Dmand AI links Dr. Metersky to 4 clinical trials, 3 of them phase 2 studies. Conditions studied include Asthma, Bronchiectasis and Scleroderma, Systemic. UConn Health sponsors the most, 2.

CMS Open Payments shows 87 general payments to Dr. Metersky from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 90% of the total. Insmed, Inc. paid the most, $64,649.

Dmand AI lists 2 awards for Dr. Metersky, most recently America's Top Doctors in 2014.

Dr. Metersky graduated from New York University School of Medicine in 1985.

Dr. Metersky is in network with 13 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.